Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Hannah Roberts

Christopher Biggins reveals he is using weight loss jabs after knee surgery

Christopher Biggins has said he uses Mounjaro (Maja Smiejkowska/PA) - (PA Wire)

Actor Christopher Biggins has revealed he is using weight loss jabs as he needed to lose weight after having surgery on his knee.

Porridge star Biggins, 76, said he is taking Mounjaro, which is made by Eli Lilly, who have joined forces with the Government in a bid to tackle obesity.

He told GB News: “I’m on Mounjaro… and I think it’s good. I mean, I had a new knee put in, and I needed to lose weight because of the pressure on the knee.”

Biggins also claimed that “they’re now finding out that this drug can cure a lot of other things” and added that “we don’t know the side effects” of it yet.

Christopher Biggins spoke to GB News (Jordan Pettitt/PA) (PA Archive)

Weight loss jabs have been hailed as transformative by health leaders.

The phased NHS roll-out of Lilly’s weight loss jab Mounjaro to patients in England started in June for people with a body mass index (BMI) over 40 and at least four co-morbidities.

Over the next three years, about 240,000 patients are expected to be eligible for the treatment.

A number of celebrities have used medication, such as Ozempic, in a bid to control their weight, including former X Factor judge Sharon Osbourne.

Wegovy and Ozempic are semaglutide drugs, while Mounjaro is another weight loss treatment called tirzepatide.

Chef Heston Blumenthal recently warned that weight loss drugs will have a negative effect on the food industry.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.